| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
13,030,000 |
| Market
Cap: |
61.89(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.05 - $22.88 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 634 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Eagle Pharmaceuticals is a pharmaceutical company focused on developing medicines to treat diseases of the central nervous system or metabolic critical care therapeutic areas as well as in oncology. Co.'s products include: Belrapzo® (bendamustine ready-to-dilute (RTD) 500ml solution), Bendeka® (infused bendamustine RTD) and Treakisym® for chronic lymphocytic leukemia and non-hodgkin's lymphoma; Ryanodex® (dantrolene sodium) for malignant hyperthermia; EP-4104 Ryanodex® (dantrolene sodium) for the treatment of organophosphate exposure; PEMFEXY™ (pemetrexed for injection) for lung cancer; and EA-114 (fulvestrant) for breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
35,245 |
87,045 |
| Total Sell Value |
$0 |
$0 |
$599,727 |
$1,741,115 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
3 |
7 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cahill Brian Joseph |
Chief Financial Officer |
• – – |
2021-01-05 |
4 |
D |
$50.02 |
$37,315 |
D/D |
(746) |
14,540 |
|
- |
|
| Cahill Brian Joseph |
Chief Financial Officer |
• – – |
2020-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
19,303 |
|
- |
|
| Cahill Brian Joseph |
Chief Financial OfficerOfficer |
• – – |
2020-10-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,286 |
|
-2% |
|
| Ratoff Steven B |
Director |
– • – |
2020-02-28 |
4 |
OE |
$8.78 |
$20,545 |
D/D |
2,340 |
20,344 |
|
- |
|
| Tarriff Scott |
CEO |
• • • |
2020-01-23 |
4 |
D |
$57.98 |
$437,633 |
D/D |
(7,548) |
1,550,954 |
|
- |
|
| Pernock David |
Pres. & Chief Comm. Officer |
• – – |
2020-01-23 |
4 |
D |
$57.98 |
$103,958 |
D/D |
(1,793) |
49,811 |
|
- |
|
| Meyers Peter A. |
Chief Financial Officer |
• – – |
2020-01-23 |
4 |
D |
$57.98 |
$95,841 |
D/D |
(1,653) |
43,615 |
|
- |
|
| Hepner Adrian |
EVP and Chief Medical Officer |
• – – |
2020-01-23 |
4 |
D |
$57.98 |
$94,507 |
D/D |
(1,630) |
48,784 |
|
- |
|
| Pernock David |
Pres. & Chief Comm. Officer |
• – – |
2020-01-07 |
4 |
D |
$57.38 |
$51,872 |
D/D |
(904) |
51,604 |
|
- |
|
| Meyers Peter A. |
Chief Financial Officer |
• – – |
2020-01-07 |
4 |
D |
$57.38 |
$36,264 |
D/D |
(632) |
45,268 |
|
- |
|
| Hepner Adrian |
EVP and Chief Medical Officer |
• – – |
2020-01-07 |
4 |
D |
$57.38 |
$46,765 |
D/D |
(815) |
50,414 |
|
- |
|
| Pernock David |
Pres. & Chief Comm. Officer |
• – – |
2020-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
21,500 |
52,508 |
|
- |
|
| Meyers Peter A. |
Chief Financial Officer |
• – – |
2020-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
19,500 |
45,900 |
|
- |
|
| Tarriff Scott |
CEO |
• • • |
2020-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
58,300 |
1,558,502 |
|
- |
|
| Hepner Adrian |
EVP and Chief Medical Officer |
• – – |
2020-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
24,000 |
51,229 |
|
- |
|
| Braunstein Douglas L |
Director |
– • – |
2019-10-25 |
4 |
AS |
$63.57 |
$981,302 |
I/I |
(15,437) |
732,777 |
|
- |
|
| Braunstein Douglas L |
Director |
– • – |
2019-10-24 |
4 |
AS |
$62.53 |
$93,412 |
I/I |
(1,494) |
748,214 |
|
- |
|
| Braunstein Douglas L |
Director |
– • – |
2019-10-23 |
4 |
AS |
$62.58 |
$12,516 |
I/I |
(200) |
749,708 |
|
- |
|
| Braunstein Douglas L |
Director |
– • – |
2019-10-22 |
4 |
AS |
$62.68 |
$411,618 |
I/I |
(6,567) |
749,908 |
|
- |
|
| Braunstein Douglas L |
Director |
– • – |
2019-10-21 |
4 |
AS |
$62.56 |
$240,791 |
I/I |
(3,849) |
756,475 |
|
- |
|
| Braunstein Douglas L |
10% Owner |
– – • |
2019-10-18 |
4 |
AS |
$62.61 |
$100,174 |
I/I |
(1,600) |
760,324 |
|
- |
|
| Braunstein Douglas L |
10% Owner |
– – • |
2019-10-17 |
4 |
AS |
$62.58 |
$866,196 |
I/I |
(13,842) |
761,924 |
|
- |
|
| Braunstein Douglas L |
10% Owner |
– – • |
2019-10-16 |
4 |
AS |
$62.50 |
$6,375 |
I/I |
(102) |
775,766 |
|
- |
|
| Braunstein Douglas L |
Director |
– • – |
2019-10-15 |
4 |
AS |
$62.63 |
$244,836 |
I/I |
(3,909) |
775,868 |
|
- |
|
| Braunstein Douglas L |
Director |
– • – |
2019-10-11 |
4 |
AS |
$60.39 |
$984,419 |
I/I |
(16,300) |
779,777 |
|
- |
|
222 Records found
|
|
Page 3 of 9 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.14 (3.04%) 
